AML3; CBFA1; OSF2; PEBP2A; Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; CBF-alpha-1; Oncogene AML-3; Osteoblast-specific transcription factor 2; OSF-2; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEA2-alpha A; PEBP2-alpha A; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit

For Research Use Only. Not for use in diagnostic procedures.

Synthetic

>85%

Lyophilized Powder

Shipped at 4 degree C. Store at -20 degree C for one year.

Small volumes of RUNX2 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The peptide is used to block Anti-RUNX2 Antibody reactivity.

Blocking (BL)

Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.

54,249 Da

runt related transcription factor 2

runt-related transcription factor 2

Runt-related transcription factor 2

AML3; CBFA1; OSF2; PEBP2A; CBF-alpha-1; OSF-2; PEA2-alpha A; PEBP2-alpha A??[Similar Products]

RUNX2_HUMAN

This gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with an Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. Mutations in this gene have been associated with the bone development disorder cleidocranial dysplasia (CCD). Transcript variants that encode different protein isoforms result from the use of alternate promoters as well as alternate splicing. [provided by RefSeq, Jul 2008]

AML3: Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'- PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Inhibits KAT6B-dependent transcriptional activation. Interaction with SATB2 results in enhanced DNA binding and transactivation by these transcription factors. Heterodimer of an alpha and a beta subunit. Interacts with HIVEP3 and HIPK3. The alpha subunit binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Interacts with XRCC6 (Ku70) and XRCC5 (Ku80). Interacts with KAT6A and KAT6B. Binds to cyclin B1 CCNB1. Interacts with DDX5. Specifically expressed in osteoblasts. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: DNA-binding; Transcription factor

Chromosomal Location of Human Ortholog: 6p21

Cellular Component: cytoplasm; nuclear chromatin; nucleoplasm; transcription factor complex

Molecular Function: ATP binding; bHLH transcription factor binding; chromatin binding; histone deacetylase binding; protein binding; protein domain specific binding; transcription factor activity

Biological Process: BMP signaling pathway; cell maturation; chondrocyte development; chondrocyte differentiation; embryonic cranial skeleton morphogenesis; embryonic forelimb morphogenesis; endochondral ossification; gene expression; hemopoiesis; negative regulation of smoothened signaling pathway; negative regulation of transcription, DNA-dependent; neuron differentiation; odontogenesis of dentine-containing teeth; ossification; osteoblast development; osteoblast differentiation; osteoblast fate commitment; positive regulation of cell proliferation; positive regulation of chondrocyte differentiation; positive regulation of osteoblast differentiation; positive regulation of transcription, DNA-dependent; regulation of cell differentiation; regulation of fibroblast growth factor receptor signaling pathway; regulation of odontogenesis of dentine-containing teeth; regulation of transcription from RNA polymerase II promoter; stem cell differentiation; T cell differentiation; transcription initiation from RNA polymerase II promoter

Disease: Cleidocranial Dysplasia; Metaphyseal Dysplasia With Maxillary Hypoplasia With Or Without Brachydactyly

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.